Skip to main content

Becton Dickinson and Company(BDX-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

BCAL Findings Presented at 2023 ASCO Annual Meeting

PR Newswire - Tue Jun 6, 2023

Highlights

SYDNEY, June 6, 2023 /PRNewswire/ -- BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) today announced the presentation of data demonstrating the potential for detection of early breast cancer using a plasma lipidomic biomarker signature. BCAL is developing a non-invasive blood screening test that is intended to be used alongside breast cancer screening methods, such as mammography. The poster, "Lipidomic Signature From Plasma to Detect Localised Breast Cancer," was presented at the 2023 ASCO Annual Meeting (Chicago, 2-6 June 2023).

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe